JERINI INITIATES PIVOTAL REGISTRATION STUDY FOR ICATIBANT IN HEREDITARY ANGIOEDEMA
Jerini announced today the start of its US and Canadian pivotal registration study with Icatibant for the treatment of hereditary angioedema (HAE). An Investigational New Drug Application (IND) and clinical trials Application (CTA) have been filed with the FDA and Health Canada, respectively. Both, IND and CTA are active. The final protocol for a European multi-center pivotal registration study will be submitted to the competent authorities and ethics committees in September. In both multi-center studies, named FAST 1 (For Angioedema Subcutaneous Treatment) in US/Canada and FAST 2 in Europe, patients will be treated with a subcutaneous formulation of Icatibant.
"We are extremely pleased with Icatibant´s rapid clinical development and are especially hopeful that HAE patients will be able to benefit from this novel medicine in the very near future," stated Jens Schneider-Mergener, CEO of Jerini.
Jerini has been granted orphan drug status by the FDA and EMEA (European Agency for the Evaluation of Medicinal Products) for Icatibant in the treatment of hereditary angioedema in the case of FDA approval. Orphan drug designation secures Icatibant seven years of market exclusivity in the United States and ten years in Europe. Moreover, Jerini received a fast track designation from the FDA for Icatibant in this indication. This designation helps to facilitate the development of the drug and expedite the review process.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Benefits of Diane 35 and its generics outweigh risks in certain patient groups - PRAC recommendation endorsed by CMDh
Grifols opens diagnostic training center in Dubai
DOR BioPharma and Cambrex Enter into a Development and Manufacturing Process Agreement for RiVax(TM)
MaxiVAX starts anti-cancer clinical trial based on active immunotherapy - Novel high-tech anti-cancer vaccination therapy boosts the patient’s own immune response
Cannabis_flower_essential_oil
Definiens Strengthens Leadership with Key Appointment - Former Aperio Executive and Digital Pathology Market Expert, Dr. Martin Stuart, Joins Executive Team
Researchers could use plant's light switch to control cells
Placenta size and offspring bone development linked
Diving_Diseases_Research_Centre
